BrainStorm Cell Therapeutics Inc. Receives FDA Clearance to Launch Phase 3b Trial of NurOwn® for ALS
I'm PortAI, I can summarize articles.
BrainStorm Cell Therapeutics Inc. has received FDA clearance to initiate a Phase 3b clinical trial of NurOwn® for ALS treatment. The trial will enroll around 200 participants at top medical centers and includes a 24-week randomized, double-blind, placebo-controlled phase, followed by a 24-week open-label extension. The primary endpoint is the change in the ALS Functional Rating Scale-Revised from baseline to week 24. An investor call and webcast are scheduled to discuss this development further.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments